428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Triple-Negative Breast Carcinoma	Fudan University	P3	B (60)
Lenvatinib Triple-Negative Breast Carcinoma	Fudan University	P2	B (60)
Letrozole Triple-Negative Breast Carcinoma	NiKang Therapeutics, Inc.	P2	B (60)
Metformin Triple-Negative Breast Carcinoma	The Methodist Hospital Research Institute	P2	B (60)
Sacituzumab Tirumotecan Triple-Negative Breast Carcinoma	Yale University	P3	B (60)
Shr-A1811 For Triple-Negative Breast Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	B (60)
Theprubicin Triple-Negative Breast Carcinoma	Xijing Hospital	P2	B (60)
Trastuzumab Triple-Negative Breast Carcinoma	Fudan University	P3	B (60)
Abemaciclib Triple-Negative Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P2	B (59)
Fluzoparib Triple-Negative Breast Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	B (59)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Triple-Negative Breast Carcinoma	Fudan University	P3	B (59)
Oxaliplatin Triple-Negative Breast Carcinoma	Pfizer	P2	B (59)
Zimberelimab Triple-Negative Breast Carcinoma	MedSIR	P2	B (59)
Cediranib Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	B (58)
Decitabine Triple-Negative Breast Carcinoma	National Cancer Institute (NCI)	P2	B (58)
Neratinib Triple-Negative Breast Carcinoma	Baylor Research Institute	P2	B (58)
Palbociclib Triple-Negative Breast Carcinoma	Avenzo Therapeutics, Inc.	P2	B (58)
Pvx-410 Triple-Negative Breast Carcinoma	OncoPep, Inc.	P2	B (58)
Retifanlimab Triple-Negative Breast Carcinoma	Incyte Corporation	P2	B (58)
Romidepsin Triple-Negative Breast Carcinoma	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	P2	B (58)
Darolutamide Triple-Negative Breast Carcinoma	Vandana Abramson	P2	B (57)
Dasatinib Triple-Negative Breast Carcinoma	Fudan University	P2	B (57)
Ddctx Triple-Negative Breast Carcinoma	Fudan University	P3	B (57)
Ddepirubicin Triple-Negative Breast Carcinoma	Fudan University	P3	B (57)
esg401 Triple-Negative Breast Carcinoma	Qilu Pharmaceutical Co., Ltd.	P3	B (57)
Fulvestrant Triple-Negative Breast Carcinoma	Pfizer	P2	B (57)
Fuzuloparib Triple-Negative Breast Carcinoma	Guangdong Provincial People's Hospital	P3	B (57)
Hypoxanthine Riboside Triple-Negative Breast Carcinoma	Fudan University	P2	B (57)
Lornoxicam Triple-Negative Breast Carcinoma	Fudan University	P3	B (57)
Nivolumab Triple-Negative Breast Carcinoma	Yale University	P2	B (57)
Panitumumab Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	P2	B (57)
Pembrolizumab/Vibostolimab Coformulation Triple-Negative Breast Carcinoma	Merck Sharp & Dohme LLC	P2	B (57)
Tinengotinib Triple-Negative Breast Carcinoma	TransThera Sciences (Nanjing), Inc.	P1/2	B (57)
Trilaciclib Triple-Negative Breast Carcinoma	Wake Forest University Health Sciences	P3	B (57)
Tucidinostat Triple-Negative Breast Carcinoma	wang shusen	P2	B (57)
Avelumab Triple-Negative Breast Carcinoma	Ocellaris Pharma, Inc.	P3	B (56)
Datopotamab Deruxtecan Triple-Negative Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P2	B (56)
Etoposide Triple-Negative Breast Carcinoma	Xijing Hospital	P2	B (56)
Huaier Granule Triple-Negative Breast Carcinoma	Fudan University	P4	B (56)
Lifileucel Triple-Negative Breast Carcinoma	Yale University	P2	B (56)
Niraparib Triple-Negative Breast Carcinoma	Zhejiang Cancer Hospital	P2	B (56)
Serplulimab Triple-Negative Breast Carcinoma	Shanghai Henlius Biotech	P3	B (56)
Talazoparib Triple-Negative Breast Carcinoma	University of Malaya	P2	B (56)
Tislelizumab Triple-Negative Breast Carcinoma	National University Hospital, Singapore	P2	B (56)
Viscum Album Triple-Negative Breast Carcinoma	Ilsan Cha hospital	P4	B (56)
Adavosertib Triple-Negative Breast Carcinoma	AstraZeneca	P2	CCC (55)
b013 Triple-Negative Breast Carcinoma	Shanghai Jiaolian Drug Research and Development Co., Ltd	P2/3	CCC (55)
Iparomilimab Triple-Negative Breast Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2/3	CCC (55)
Olinvacimab Triple-Negative Breast Carcinoma	PharmAbcine	P2	CCC (55)
Pyrotinib Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (55)

Showing 51 to 100 of 428 assets

PreviousPage 2 of 9Next